Newsgroup: it.economia.borsa
Titolo: 18.01.07 08:26 - Novartis: salgono utili e ricavi 4* trim. -2-

Il fatturato invece e' salito del 16% in un anno, da 8,66 a 10,05 miliardi
di dollari, in questo caso battendo le attese del mercato ferme a 9,66
miliardi di dollari.
Per l'anno 2006 il dividendo e' stato alzato da 1,15 a 1,35 franchi
svizzeri, mentre per il 2007 ci si aspetta un anno record per utili e
ricavi, ha detto il Ceo Daniel Vasella, che non esclude un'offerta sulla
divisione farmaci generici della tedesca Merck Kgaa "anche se non c'e'
fretta". Cosi' come non c'e' fretta per dimettere glio asset nutrizionali
con marchio Gerber, che "non sono parte del nostro core business ma vanno
comunque bene" ha detto l'Ad. mm
(END) Dow Jones Newswires
January 18, 2007 02:26 ET (07:26 GMT)
© 2007 MF-Dow Jones News Srl.
UPDATE: Novartis Profit Climbs 23% On Blood Pressure, Cancer Drugs
By Steve Goldstein
LONDON (Dow Jones) -- Swiss drugmaker Novartis AG on Thursday reported a 23% 
rise in fourth-quarter net profit, helped by medications to treat high blood 
pressure and cancer ailments and by copycat drugs.
Novartis (NVS) said fourth-quarter profit rose 23% to $1.66 billion, or 70 
cents a share, with sales up 16% to $10.05 billion.
On an annual basis, profit rose 17% to $7.2 billion, or $3.04 a share, on 
15% sales growth to $37.02 billion.
For the year, analysts expected earnings of $3.09 a share on revenue of 
$36.76 billion. The earnings shortfall was in part due to a contract lens 
recall and more merger-related costs than anticipated, said J.P. Morgan 
analyst Craig Maxwell in a note to clients.
Shares in Novartis slipped 0.4% in moderately higher Swiss market.
During the quarter, sales of hypertension drug Diovan rose 16% to $1.15 
billion and sales of Gleevec, a leukemia drug, rose 19% to $702 million.
Sales of high-blood pressure treatment Lotrel rose 19% to $354 million, and 
sales of breast cancer drug Femara climbed 40% to $204 million.
The company was able to hold operating margins in its main pharmaceutical 
division steady at 29.7% during the course of the year.
With the launch of diabetes drug Galvus and hypertension drugs Tekturna and 
Exforge, analysts are questioning if Novartis can hold margins at that level 
in 2007 while hiring more sales representatives to market the products.
The company didn't give margin guidance for 2007, though it said the 
pharmaceutical unit should post a mid-single-digit percentage rise in sales.
"We continue to see pressure on 2007 margins from product launches with no 
improvement despite lower one-off charges from the Chiron acquisition," said 
Graham Parry, an analyst at Merrill Lynch, in a note to clients.
More vaccines shipped
Elsewhere, the company's vaccine sales rose 71% when compared to the 
performance at then-partly owned Chiron last year, driven by U.S. deliveries 
of seasonal flu vaccines. Chiron's plants, notably in Liverpool, England, 
were dogged in 2005 by manufacturing problems.
Its Sandoz division, which makes generic drugs, posted a 71% rise in 
operating profit on just 5% sales growth. New products launched into Germany 
and the benefit of its acquisitions of Hexal and Eon Labs boosted profit, 
the company said. The year-ago quarter also had four months of Eon Labs 
sales, Novartis pointed out.
Daniel Vasella, chief executive, said in an interview with CNBC Europe 
television that "several parties" have expressed interest in its Gerber baby 
food unit, following publication of an article in The Wall Street Journal 
that Nestlemay try to buy it.
Nestle in December agreed to buy the medical nutrition business of Novartis 
for $2.5 billion.
But Vasella added that no talks are going on for the Gerber unit, which 
Vasella said was not core to the company.
(END) Dow Jones Newswires
01-18-070648ET
Copyright (c) 2007 Dow Jones & Company, Inc.
da WALL STREET JOURNAL

 comunque bene" ha detto l'Ad. mm
Grazie ZIO BART !!
Sei sempre una delle ultime grandi colonne rimaste sul IEB.
Salgono utili, saliranno dividendi e saliranno anche le "stock Options" in
mano alla mia Nipote TIZIANA , attualmente Resposabile per i Mercati
dell'EST della Grande Casa Farmaceutica.Che carriera !
Entro' alla Bering, che fu poi assorbita da CAIRO il colosso Americanp,
che a suo volta cedette tutto appunto a NOVARTIS.  La Filiale italiana e'
a OGGIONO... purtroppo Tiziana restera' a SIENA ancora per qualche mese.
Pensa che strano incrocio.    Il mio Amico BERTARELLI ha ceduto la SERONO
proprio alla MERCK che tu citi nel tuo intervento.
Mannaggia 'sti svizzeri !!  che dritti. Fanno affari anche loski affari
con tutti. Fortunati loro non hanno la sventura di avere un Governo
katto-verde-komunista !
Il Pauletto.
-- 
www.pixagogo.com/7989034617
Grafici Storici-Weekly e INTRADAY
questo articolo e` stato inviato via web dal servizio gratuito 
http://www.newsland.it/news
 segnala gli abusi ad 
ab...@newsland.it

 a OGGIONO... purtroppo Tiziana restera' a SIENA ancora per qualche mese.
grande paulč,
perň nun ce fa perde temo in chiacchiere, dě a tua nipote tiziana di dacci 
le news su novartis, su ciofell e su ziotax prima dell'altri,
ehhh, capitto????
un abbraccione
:-))